



Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells

This is the peer reviewed version of the following article:

Original:

Solini, A., Sebastiani, G., Nigi, L., Santini, E., Rossi, C., Dotta, F. (2017). Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. *DIABETES & METABOLISM*, 43(6), 512-520 [10.1016/j.diabet.2017.04.002].

Availability:

This version is available <http://hdl.handle.net/11365/1008226> since 2018-07-27T13:34:31Z

Published:

DOI:10.1016/j.diabet.2017.04.002

Terms of use:

Open Access

The terms and conditions for the reuse of this version of the manuscript are specified in the publishing policy. Works made available under a Creative Commons license can be used according to the terms and conditions of said license.

For all terms of use and more information see the publisher's website.

(Article begins on next page)

Dapagliflozin modulates glucagon secretion in a SGLT2-independent manner
in murine alpha-cells

*Anna Solini¹, Guido Sebastiani², Laura Nigi², Eleonora Santini³, Chiara Rossi³, *Francesco Dotta²

¹Department of Surgical, Medical, Molecular and Critical Area Pathology, University of Pisa, Italy

²Department of Medicine, Surgery and Neuroscience, University of Siena and Fondazione Umberto di Mario-Toscana Life Science, Siena, Italy; ³Department of Clinical and Experimental Medicine, University of Pisa, Italy

Short running title: Dapagliflozin and glucagon secretion

***Corresponding Authors**

Anna Solini, MD PhD
Department of Surgical, Medical, Molecular and Critical Area Pathology
University of Pisa
I-56126 Pisa, Italy
Ph: +39-050-993482
Fax: +39-050-553235
Email: anna.solini@med.unipi.it

Francesco Dotta, MD
Department of Medicine, Surgery and Neuroscience
University of Siena
I-53100 Siena, Italy
Ph: +39-0577-586269
Fax: +39-0577-586186
Email: francesco.dotta@unisi.it

Abstract

Aim SGLT2 inhibitors reduce renal glucose uptake with an insulin-independent mechanism. They also increase glucagon concentration; to which extent this is due to a direct effect on pancreatic alpha-cells remains unclear.

Methods In the present work, α TC-1 cells treated with the SGLT2 inhibitor Dapagliflozin (Dapa), were analyzed in terms of glucose transporters, molecular mediators of hormone secretion, glucagon and GLP-1 release, effects of somatostatin. Data were validated in murine and human pancreatic islets.

Results *Slc5a2* (SGLT2-encoding gene) was almost undetectable in α TC-1 cells, even by digital PCR technique with different probes. In contrast, *Slc5a1* (SGLT1-encoding gene), was constitutively abundant in α TC-1 and in islets, and was increased by Dapa; this was associated to a higher glucagon release, preceded by increased expression of Pre-proglucagon and Hepatocyte nuclear factor-4 α . Looking at the candidate intracellular signaling pathway, reduced PASK and increased AMPKa2 expression was detected. GLUT1 and GLUT2 as well as regulators of glucagon release or of alpha-cell phenotype (Chromogranin-A, Paired Box-6, Proconvertase1/2, Synaptophysin) were unaffected by Dapa treatment, similarly to GLP-1 receptor expression or GLP-1 release. Low glucose did not influence the stimulatory effect of Dapa on glucagon release, which, instead, was almost fully reverted by *Slc5a1* silencing. The effect of Dapa on adenosine monophosphate-activated protein kinase (AMPK) and per-arnt-sim kinase (PASK), emerging regulators in lipid and glucose metabolism, was tested; an up-regulated AMPK-a2 seems to be the involved molecular signaling.

Conclusion We show here that in α TC-1 cells Dapa acutely upregulates SGLT1 expression and increases glucagon release with a SGLT1-dependent mechanism, with SGLT2 expression virtually undetectable. These results suggest an involvement of SGLT1 in modulating glucagon increase following SGLT2 inhibition.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

Keywords SGLT2 inhibitors; SGLT1; glucagon; alpha-cells.

Introduction

1
2
3
4 SGLT2 inhibitors are novel drugs recently introduced in the market for the treatment of type 2
5
6 diabetes (T2DM). They induce glycosuria acting at the renal level by a fully insulin independent
7
8 mechanism [1]; however, their administration determines several other relevant clinical effects, like
9
10 a reduction of body weight due a true loss of calories, and a reduction in systolic blood pressure,
11
12 mainly dependent upon a thiazide-like diuretic effect [2]. Besides these positive clinical actions,
13
14 administration of SGLT2 inhibitors induces some potentially undesirable metabolic responses, like
15
16 a raise in endogenous glucose production and increased glucagon levels. These observations,
17
18 initially performed in two landmark clinical studies [3, 4] have casted doubts on the previously
19
20 claimed almost exclusive presence of SGLT2 cotransporters in the kidney. In rodents and bovines,
21
22 SGLT2 expression has been found in mammary gland [5, 6], while in humans SGLT2 has little or
23
24 no detectable level in tissues other than renal cortex and medulla [7]. Recently, Bonner *et al* have
25
26 documented the presence of SGLT2 in murine alpha-cells and in human pancreatic islets, where it
27
28 appears responsible for an increased glucagon secretion [8]. However, glucagon secretion is an
29
30 extremely complex issue, only partially known and certainly regulated by several mechanisms,
31
32 ranging from paracrine effects of insulin and somatostatin to autonomic nervous system, from
33
34 energy availability (changes in the ATP/ADP ratio) to intracellular ion fluxes [9-11]. Moreover, a
35
36 role for SGLT1 cotransporters, in this scenario, cannot be ruled out: for example, SGLT2 inhibition
37
38 by highly selective molecules, like those used for the treatment of T2DM, might induce a hyper-
39
40 expression of SGLT1, likely responsible, in the kidney, for an enhanced glucose reabsorption in the
41
42 distal tract of the proximal tubule, thereby limiting the therapeutic efficacy of these drugs [12].
43
44 SGLT1 seems also to be active in specific regions of the brain such as the hippocampus [13], thus
45
46 contributing to glucose homeostasis, possibly through mechanisms other than the renal/gut glucose
47
48 reabsorption; we may therefore hypothesize that above mentioned properties of SGLT1, as well as
49
50 of other cotransporters, have yet undiscovered physiological significance.
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 In order to gain further insight into the mechanisms underlying the effect of selective SGLT2
2 inhibition on glucagon secretion, we designed the present study in a cellular model of alpha cells,
3
4 trying to better define the role of SGLT2 and SGLT1 transporters in this crucial metabolic response.
5
6
7
8
9
10

11 **Research Design and Methods**

12
13
14
15
16
17 *Cells and reagents* - Murine α TC-1 (clone 6) cells were obtained from ATCC (ATCC® CRL-
18
19 2934). Dapagliflozin (Dapa) was kindly provided by Astra Zeneca Int. Somatostatin was purchased
20
21 by Hikma, Jordan.

22
23
24 *Study protocol* - α TC-1 cells (20th passage) were cultured in Dulbecco's modified Eagle medium
25
26 containing 25 mmol/l Glucose (Sigma-Aldrich, St Louis, MO, USA), 10% FBS (Gibco, Thermo-
27
28 Fisher Scientific Waltham, MA, USA), 100 units/ml penicillin, and 100 μ g/ml streptomycin, were
29
30 maintained at 37°C/5% CO₂, changing media every three days; this high-glucose medium is
31
32 commonly used to grow this cellular clone [14, 15]. Cells were seeded at equal density in six-well
33
34 plates and incubated with 100 ng/ml Dapa for different time courses (30, 45, 60, 120, 240, 480 and
35
36 720min). Such Dapa concentration was chosen because corresponding to the mean therapeutic
37
38 plasma concentration reached during treatment with this SGLT2 inhibitor in humans [16]. Media
39
40 were collected and cells were lysed for mRNA and protein extraction. Some experiments were
41
42 repeated after switching cells to starvation media (DMEM containing glucose 1.1 or 5.5 mmol/l, 1.5
43
44 g NaHCO₃, 0.25% BSA, and 15 mmol/l HEPES) and incubating them for 30, 45, 60, 120, 240 and
45
46 720min, to explore the effect of low glucose levels on hormone release.
47
48
49
50
51

52
53 *Transfection and gene silencing* - α TC-1 cells were plated at a density of 2×10^5 /well in 24-wells
54
55 plate and transfected 24h later. *Slc5a1* silencing in α TC-1 cells was performed using Lipofectamine
56
57 3000 (1.5 μ l/well) and Stealth siRNA oligonucleotide targeting *Slc5a1* gene (set of three:
58
59 (MSS209159, MSS209160, MSS277112, from Applied Biosystems, Foster City, CA, USA) or
60
61
62
63
64
65

1 scrambled siRNA oligonucleotide at a final concentration of 100nM following manufacturer's
2 instructions. Transfection medium was changed after 24h and cells were maintained for further 48h
3
4 before proceeding with Dapa treatment for 30min and 240min. Knockdown efficiency was
5
6 confirmed by Real-Time quantitative PCR and by digital PCR using specific assays.
7
8

9 *Laser capture microdissection (LCM)* - Pancreatic murine tissue samples obtained from C57BL/6J
10 mice, were frozen in O.C.T. compound (Sakura-Fintek, Torrance, CA, USA) and 8- μ m sections
11
12 were prepared. Sections were fixed in 70% ethanol for 30s, rinsed in RNase-free water for
13
14 5seconds, stained with Mayer's hematoxylin solution and finally dehydrated. LCM was performed
15
16 using Arcturus XT system (Arcturus Engineering, Mountain View, CA, USA) by melting
17
18 thermoplastic films mounted on transparent LCM caps (HS-Caps) (Arcturus) on specific islet areas
19
20 (islet core and islet periphery) as previously shown [17]. Captured cells were lysed and then stored
21
22 at -80°C until RNA extraction.
23
24
25
26
27

28 *Human pancreatic islets* - Collagenase-isolated human pancreatic islets obtained from 3 non-
29
30 diabetic multiorgan donors (BMI 26.3 \pm 2.5 Kg/m²; age 59.7 \pm 12.7 years; 2M, 1F) were purchased
31
32 from Lonza (Walkersville, MD, USA). Upon arrival, pancreatic islets were maintained in culture
33
34 using CMRL-1040 supplemented with 10% FBS, L-Glutamine 1mmol/l and 1X
35
36 Antibiotic/Antimycotic for 24h before being processed for experiments.
37
38

39 *Gene and protein expression studies* - Expression of *Slc5a1*, *Slc5a2*, *Slc2a1* and *Slc2a2* genes,
40
41 encoding for SGLT1, SGLT2, GLUT1 and GLUT2 respectively, was quantified by real-time and
42
43 digital PCR. Briefly, total RNA was extracted using RNeasy mini kit (QIAGEN GmbH, Hilden,
44
45 Germany) or Picopure RNA isolation kit (for LCM captured cells). Extracted RNA from LCM
46
47 captured cells were tested for RNA integrity using 2100 Bioanalyzer instrument (Agilent
48
49 Technologies, Santa Clara, CA, USA) taking into consideration only those samples with a RIN
50
51 (RNA Integrity Number) >5.0. cDNA was produced using High Capacity cDNA Reverse
52
53 Transcription Kit (Applied Biosystems, Foster City, CA, USA) following manufacturer's
54
55 instructions, followed by a pre-amplification step as previously described [13]. Real-time PCR was
56
57
58
59
60
61
62
63
64
65

1 performed in triplicate on an Eco-Real Time instrument (Illumina Inc., San Diego, CA, USA) and
2 on a VIIA7 instrument (Applied Biosystems) following a standard protocol with specific TaqMan
3 Gene Expression Assays. **Suppl. Table A** reports indications on all probes used in Real-Time PCR
4 analyses. *Ct* values (cycle threshold) were used to calculate the amount of amplified PCR product
5 relative to β -actin, and the relative amount of mRNA was calculated as $2^{-\Delta\Delta C_t}$. Results are expressed
6 as fold change above reference sample.
7
8
9
10
11
12

13 The relative expression of *Slc5a2* gene was analyzed using different TaqMan assays (SGLT2-A,
14 -B,-C,-D, Suppl. Table A) mapping along the gene, to avoid biases due to any potential spliced
15 forms. For this gene, we also carried out an absolute gene expression quantification using digital
16 PCR (ddPCR QX200, Bio-Rad, Hercules, CA, USA). Briefly, the same TaqMan Gene Expression
17 assays (SGLT2-B and -D) were adapted to ddPCR, and experiments were performed as follows: 1
18 cycle at 95°C for 10min, 44 cycles at 95°C for 30s and 60°C for 1min, 1 cycle at 98°C for 10min,
19 all at a ramp rate of 2°C/s (a conventional thermal cycler was used for the PCR step). The positive
20 droplets were quantified using the Bio-Rad QuantaSoft software and the number of target molecules
21 in each sample was estimated according to Poisson distribution.
22
23
24
25
26
27
28
29
30
31
32
33
34
35

36 *Western Blot analyses* - 20 μ g of total protein extracts were diluted in SDS-PAGE buffer and heated
37 at 100°C for 5min. Samples and molecular weight markers were electrophoresed on Any kD Mini-
38 Protean TGX gels and transferred to PVDF membrane. After a blocking step using BSA 3% in
39 TTBS (TBS and Tween-20 0.05%) for 1h at room temperature, blots were repeatedly washed in
40 TTBS and incubated overnight at 4°C with the following primary antibodies diluted 1:100: SGLT1
41 (sc-98974), SGLT2 (sc-393350) PASK (sc-74812), AMPK-a2 (sc-19129), pAMPK-a2 (2535 S), β -
42 actin (sc-47778) and GAPDH (CAB932Hu22), purchased from Santa Cruz Biotechnology, Dallas,
43 TX, USA; Cell Signaling Technology, Danvers, MA, USA; Cloud-Clone Corp, Houston TX,
44 USA). To confirm the band specificity, anti-SGLT2 antibody (cat. 3690-100, BioVision
45 Incorporated, Milpitas, CA, USA) diluted 1:200 was blocked by incubation with an equal volume of
46 control peptide (cat. 3690BP, BioVision) for 30min at 37°C. Bands were detected by incubating the
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 blot with species-specific secondary antibodies, followed by enzymatic chemiluminescence, and
2 quantified by densitometric analysis using Image J software (NIH, Bethesda, MR, USA).
3

4 *Glucagon secretion and its modulation* - Aliquots of α TC-1 cell culture supernatants were collected
5 and assayed for glucagon release; cellular glucagon content was also determined from cellular
6 lysates in 0.1 mmol/l HCl. Hormone concentrations were measured by radioimmunoassay
7 (Millipore Corp., Billerica, MA, USA). Release was measured as absolute value (pg/ml/ μ g protein)
8 and referred to intracellular content [(surnatant/surnatant+content). 100; expressed as %].
9

10 Expression of alpha-cell genes of interest (Chromogranin A, Paired Box 6 [PAX6],
11 Proconvertase1/2, Synaptophysin, ARX) was quantified by Real-Time PCR as described above;
12 primers and probes are reported in **Suppl. Table A**.
13

14 *Glucagon-like peptide 1 (GLP-1) receptor expression and GLP-1 release* - GLP-1 receptor
15 expression was analyzed by real-time PCR in α TC-1 cells, before and after treatment with Dapa 100
16 ng/ml for 30, 45, 60 and 720min. GLP-1 release was assessed using a RIA kit (Millipore Corp.).
17

18 *Effect of somatostatin* - α TC-1 cells grown in standard conditions were pre-incubated with
19 somatostatin 1 μ g/ml, alone or in combination with Dapa, for 240 and 720min, to assess the effect
20 of somatostatin on the expression of its receptor (measured by Real-Time PCR) and on glucagon
21 release.
22

23 *Intracellular signaling* - PASK, total and phosphorylated AMPK-a2, PKC α and SNAP25 were
24 assessed by Real-time PCR and western blot analysis as described above.
25

26 *Statistical analysis* Data are reported as means \pm SD. Group differences were analyzed by two-
27 way ANOVA for repeated measures and post hoc Bonferroni-Dunn test, with medium glucose
28 concentration (5.5 or 1.1 and 22 mM) as main factor. A *P* value <0.05 was considered statistically
29 significant.
30

Results

1
2
3
4
5 *Expression of glucose transporters* - Murine α TC-1 (clone-6) cells constitutively expressed *Slc5a1*,
6
7 *Slc2a1* and *Slc2a2* genes, encoding respectively for SGLT1, GLUT1 and GLUT2 transporters (**Fig.**
8
9 **1A**). Treatment of α TC-1 cells with Dapa did not influence either *Slc2a1* or *Slc2a2* gene
10
11 expression, while *Slc5a1* (encoding for SGLT1) was promptly and significantly upregulated,
12
13 ranging from a 90% increase after 30min to 35% after 60min.
14
15

16
17 Unexpectedly *Slc5a2* (encoding for SGLT2) was only, and minimally, detectable using digital-PCR
18
19 technique (**Fig. 1B**). The extremely low expression of this gene was even more evident when
20
21 compared to murine kidney, and was confirmed by Western Blot analysis: even when a large
22
23 amount of total protein (100 μ g) was loaded for alpha-cells, the specific SGLT2 band was only
24
25 barely detectable, despite the use of a highly specific antibody (demonstrated by the lack of signal
26
27 when a control peptide was co-incubated, **Fig. 1C**).
28
29
30

31
32 In pancreatic murine samples, *Slc5a1* was differentially expressed in specific islet areas (islet
33
34 periphery vs core) isolated by LCM: while *Slc5a2* was almost undetectable in both areas, *Slc5a1*
35
36 expression was increased in the peripheral cell population (enriched in alpha-cells) respect to core
37
38 cell population (enriched in beta-cells) (**Fig. 2A**); the different composition of these two islet areas
39
40 was confirmed by the preferential expression of insulin and pre-proglucagon genes in the core or in
41
42 the periphery, respectively (**Fig. 2A**). The much higher expression of *Slc5a1* vs *Slc5a2* was also
43
44 shown in human pancreatic islets from non-diabetic individuals (**Fig. 2B**); we were also able to
45
46 confirm the increased SGLT1 protein expression, while SGLT2 protein was almost undetectable in
47
48 human islets (**Fig. 2B**), despite the use of two different antibodies. **Fig. 2C** shows an example of
49
50 islet area before and after laser capture microdissection.
51
52
53
54

55
56 *Glucagon release* - Dapa stimulated glucagon release; such increment, significant for short-term
57
58 incubations, reached a mean 40% increase when we evaluated a more prolonged time course (**Fig.**
59

60
61 **3**). ~~after 720 min glucagon release was massive in both unstimulated and Dapa-treated cells.~~
62
63
64
65

1 Moreover, Dapa was able to increase the expression of pre-proglucagon as well as of HNF4 α , a
2 transcription factor, which modulates glucose transporters expression in human alpha-cells.
3

4 Conversely, the expression of a series of genes (Chromogranin A, Pax6, Pcsk1; Pcsk2,
5 Synaptophysin, ARX) modulating alpha-cell phenotype or glucagon release was not influenced by
6
7 Dapa treatment (**Suppl. Table B**).
8
9

10
11 *Effects of different glucose concentrations* - Low glucose (5.5 mM) *per se* did not significantly
12 influence glucose transporters gene expression, even after 4 hours of exposition (**Suppl. Table C**).
13

14 However, in α TC-1 cells, the stimulatory effect of Dapa on *Slc5a1* expression was maintained,
15
16 while no effect on *Slc2a1* or *Slc2a2* was observed (**Suppl. Table C**). This was paralleled by the
17 same effect on glucagon release observed in high glucose, *i.e.* an enhanced release induced by Dapa
18
19 at 1.1 mM and 5.5 mM glucose concentrations after 45-60min incubation (**Fig. 4**); noteworthy,
20
21 glucagon absolute levels were slightly higher in the presence of 1.1 mM glucose.
22
23

24
25 *GLP-1 axis evaluation* - Pre-proglucagon is a common precursor not only of mature glucagon, but
26
27 also of other secretory products of alpha-cells, like GLP-1; therefore, we tested GLP-1 receptor
28
29 gene expression and GLP-1 release in α TC-1 cells, observing that neither the former (slightly
30
31 expressed in these cells) nor the latter were influenced by treatment with Dapa (**Suppl. Figure 1**).
32
33

34
35 *Effect of somatostatin on α TC-1 cells* - Our next step was to test whether somatostatin might be
36
37 somehow involved in modulating the secretory response upon Dapa treatment. Data are reported in
38
39 **Suppl. Figure 2**. Upon 240 min treatment, somatostatin alone was unable to significantly affect
40
41 glucagon release; after 720 min, glucagon release was increased by 20% by Dapa and reduced by
42
43 20% by somatostatin (**Suppl. Fig. 2A**); however, when combined with somatostatin, Dapa was
44
45 unable to reverse or partially counteract somatostatin effect. Dapa did not exert any effect on
46
47 somatostatin receptor expression (**Suppl. Fig. 2B**).
48
49
50
51
52

53
54 *Slc5A1 gene silencing* - To confirm that Dapa-induced glucagon release involves the activity of
55
56 SGLT1, we silenced its encoding gene by siRNA transfection followed by measurement of
57
58 glucagon release upon Dapa treatment. As shown in **Figure 5**, an effective *Slc5a1* gene silencing
59
60
61
62
63
64
65

1 was documented both by Real-Time and digital PCR (**Fig. 5A and 5B**). As expected, an increase of
2 pre-proglucagon gene expression upon Dapa treatment was observed; such increase was abolished
3 upon *Slc5a1* silencing and, when silenced cells were challenged for 30 min with Dapa, a reduced
4 pre-proglucagon gene expression was evident (**Fig. 5C**). Accordingly, glucagon release, increased
5 by Dapa, did not vary in silenced cells, being not influenced by the concomitant presence of Dapa
6 for 60min (**Fig. 5D**). This early phenomenon was also confirmed in silenced cells treated with Dapa
7 for 240min.

8
9
10
11
12
13
14
15
16
17 *Effects of Dapa on intracellular signaling* - In order to unveil putative molecular mechanism(s)
18 potentially mediating the effect of Dapa on glucagon release, the following genes involved in
19 signaling pathways of interest were explored: PAS Domain Containing Serine/Threonine Kinase
20 (PASK) and total and phosphorylated AMP-activated protein kinase-2 (AMPK-a2); the former is
21 expressed in murine pancreatic beta- and alpha-cells and its overexpression in α TC-1 cells and in
22 human Langerhans islets inhibits glucagon release [18], while the latter has been recently
23 demonstrated to stimulate glucagon release [19]. Untreated cells similarly express the two kinases; a
24 short-term (30 min) incubation with Dapa significantly up-regulated AMPK-a2, while PASK was
25 unchanged. When *Slc5a1* was silenced, AMPK-a2 was down-regulated by approximately 50%,
26 although not influenced by Dapa (**Fig. 6A**); PASK did not significantly vary, confirming the lack of
27 effect of Dapa on this pathway. Data at protein level, obtained in cells treated with Dapa for 4 h,
28 confirmed the results of gene expression (**Fig. 6B**); more in detail, Dapa increased **total and, even**
29 **more, phosphorylated AMPK-a2**, and *Slc5a1* silencing partially blunted this response, in terms of
30 a **strong reduction of the total isoform** and no appreciable variation of the phosphorylated one.

31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

When cells were exposed to low glucose concentrations, AMPK-a2 was significantly ($p<0.05$)
upregulated and PASK was down-regulated ($p<0.01$); Dapa did not further enhance this effect (**Fig.**
6C).

As mediators of intracellular signaling and of glucagon release mechanism, *Prkca* and *Snap25*
expression was also evaluated upon 30 and 45min of Dapa treatment, with or without *Slc5a1*

1 silencing; however, no significant change in the expression of these kinases was observed (Suppl.
2 **Fig. 3**).
3

4 5 6 7 8 9 **Discussion**

10
11
12 The main novelty of the present study is the evidence for a relevant role of SGLT1 cotransporter in
13
14 mediating glucagon release induced by SGLT2 inhibition.
15
16

17
18 The cellular model we have used somehow turned out as ideal to identify a potential role of SGLT1,
19
20 because these cells do not express SGLT2 at any physiologically valuable level, while SGLT1 is
21
22 constitutively well represented. The recently published paper by Bonner and colleagues [8]
23
24 demonstrated that both SGLT1 and SGLT2 are expressed in human alpha-cells, while both are
25
26 scarcely represented or absent in beta-cells. Here, we additionally showed that SGLT1 is
27
28 predominantly expressed over SGLT2 not only in α TC-1 cell line, but also in laser-capture
29
30 microdissected mouse primary alpha-cells and in human native pancreatic islets. A more relevant
31
32 presence of SGLT2-encoding gene in the paper by Bonner could be likely due to technical
33
34 differences (a pre-amplification of nucleic acids magnifying the detection of scarcely expressed
35
36 molecules, while we worked on constitutive expression of tissues and cells) or, less likely, to the
37
38 use of a different α TC-1 clone. In support of our data, a recently deposited complete dataset
39
40 describing transcriptome analysis of human alpha- and beta-cells sorted from pancreatic islets of
41
42 non-diabetic donors [20], reported: *a*) the expression enrichment of SGLT1 in alpha-cells vs beta-
43
44 cells; *b*) the predominant expression of SGLT1 over SGLT2 (expression ranking based on signal
45
46 intensity from microarray: SGLT1 3779/40030; SGLT2 24718/40030) in alpha-cells, further
47
48 demonstrating the prevalence of SGLT1 expression in alpha-cells respect to SGLT2.
49
50
51
52
53
54
55
56
57

58 Another reflection is that the effect of Dapagliflozin in increasing SGLT1 expression is selective,
59
60 both in terms of gene modulation and of secretory products: as a matter of fact, the expression of
61
62
63
64
65

1 GLUT1, *i.e.* the main glucose transporter of alpha-cells (where glucose transport is indeed much
2 lower than in beta-cells) [21] and GLUT2, a key beta-cell specific transporter, usually scarcely
3 represented in alpha-cells [22], does not vary following Dapagliflozin treatment.
4

5
6
7 The increased expression of SGLT1 is paralleled by a raise in glucagon release that rapidly occurs
8 and remains stable along quite a long time frame; it is quantitatively relevant and may well explain
9 the increase reported in *in vivo* studies [3, 4]. Hormone release and its intracellular content are both
10 increased along the whole time-frame of the experiment, suggesting an early increase in newly-
11 synthesized hormone production; a role for an enhanced release of cellular glucagon depots is
12 plausible at the end of the observed time-course, and could be tentatively ascribed to glucotoxicity
13 itself, as recently suggested [23]. This is confirmed by the observation that the effect of
14

15
16
17 Dapagliflozin on glucagon release was preceded by an early and significant upregulation of pre-
18 proglucagon gene, a prohormone that, after selective enzymatic cleavage, also encodes GLP-1,
19 GLP-2, oxyntomodulin and glicentin [24]. However, Dapagliflozin does not modulate either GLP-
20 1 release or the expression of GLP-1 receptor (a G-protein linked to cAMP signaling); this
21 observation is intriguing, representing a further and indirect confirmation of the specificity and
22 selectivity of the drug effect on glucagon, and not on the whole secretory pattern of the alpha-cell.
23

24
25
26 A fully active GLP-1 system, mainly localized in alpha-cells, has been recently described in human
27 islets [25]; in this view, such selective effect and the lack of interference with the GLP-1 axis is
28 welcome under the clinical viewpoint.
29

30
31
32 Another transcription factor upregulated by Dapagliflozin in this experimental model is HNF4 α ,
33 highly expressed in murine [8] and human alpha-cells, downregulated by hyperglycemia, and
34 promoter of the trans-differentiation of alpha into beta-cells [26]. In this scenario, by a pure
35 speculation, beside the reduction of glucose toxicity, Dapagliflozin might indirectly contribute to
36 maintain an adequate beta-cell number and function through the increased HNF4 α expression. On
37 the other hand, the lack of variation in the expression of other transcription factors, such as
38 Chromogranin A (that affects islet composition and increases alpha-cell function), PAX6 (able to
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1 influence acute glucagon secretion in response to glucose and palmitate), Proconvertase 1/2
2 (endoproteolytic enzymes that regulate alpha-cell secretory pathway) or Synaptophysin (a marker of
3 differentiated islet endocrine cells) [27] in Dapagliflozin-treated cells supports the hypothesis of a
4 mere effect on the release pattern, rather than on the whole alpha-cell machinery. Even ARX, a
5 gene essential for alpha-cell differentiation, whose functional inactivation promotes the
6 reprogramming of alpha to beta-cells was not influenced by Dapagliflozin [28, 29].

7 The main physiologic stimulus for glucagon release is represented by low glucose levels; therefore,
8 we tested whether or not pulses of low glucose would modify the secretory response to
9 Dapagliflozin. Overall, the response is preserved, both in terms of expression of SGLT1 encoding
10 gene and of glucagon release, and α TC-1 cells confirm the capacity to adjust their secretory
11 response according to environmental glucose. *Slc5a1* gene silencing confirms our hypothesis of a
12 key role of this transporter in mediating this selective hormonal response. As expected, GLUT2
13 expression is slightly but significantly higher in the presence of low glucose respect to that found at
14 25 mmol/l glucose; this response, in an integrated biological system, can be regarded as a
15 potentially defensive action toward hypoglycemia.

16 Paracrine mechanisms regulating glucagon secretion involve the release of inhibitory factors like
17 somatostatin and, accordingly, blockade of alpha-cell somatostatin receptors increases glucagon
18 secretion [30]. We here show that this regulatory mechanism is not affected by SGLT2 inhibition,
19 neither somatostatin receptor expression varied upon stimulation with Dapagliflozin, adding
20 knowledge to the global metabolic effect of Dapagliflozin, also considering that in the *in vivo* study
21 documenting a raise of glucagon following its administration, somatostatin levels were not
22 measured [3].

23 Lastly, in an attempt to explore intracellular pathways mediating the enhanced glucagon release
24 induced by Dapagliflozin, we found an interesting effect of this drug on the reciprocal balance
25 between PASK and AMPK-a2. In standard conditions, the effect of Dapagliflozin on glucagon
26 secretion seems to take place *via* an activation of the pro-release kinase (i.e. AMPK-a2, with a

1 prevalent upregulation of its phosphorylated isoform), rather than a down-regulation of the anti-
2 release one (*i.e.* PASK). This hypothesis fits with the effect of *Slc5a1* silencing on both these
3 kinases, at mRNA as well as at protein level: Dapagliflozin mainly increases phosphorylated
4 AMPK-a2 while, in cells silenced for *Slc5a*, **it strongly reduces the total isoform with no**
5 **appreciable effect on the phosphorylated isoform (likely for a different half-life of the two**
6 **isoforms)**, confirming the key role of the kinase as **main** mediator of this effect.
7

8
9
10
11
12
13
14 Noteworthy, this effect is quite different to that induced by low glucose, the most powerful stimulus
15 of glucagon production and release in these cells (usually grown in high glucose concentrations): in
16 such experimental setting, low glucose down-regulates PASK and, in parallel, stimulates AMPK-a2
17 up-regulation, while the effect of Dapagliflozin on both kinases is blunted. This suggests that
18
19
20
21
22
23
24 SGLT2 inhibitors, even participating in the regulation of glucagon secretion, cannot overcome its
25 main driver, *i.e.* hypoglycemia, mimicked by low glucose culture media in this experimental setting.
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

Conclusions

1 In a murine model of alpha-cells largely used for studying the physiology and pharmacology of
2 glucagon secretion, we have unveiled a role for SGLT1 in modulating the promoting effect of
3
4 Dapagliflozin, a highly selective SGLT2-inhibitor, on glucagon release. This effect does not seem
5
6 to involve other secretory activities of alpha-cells. Therefore, we might hypothesize that, even in the
7
8 presence of a high renal SGLT2 selectivity, Dapagliflozin is still able to exert a physiologically
9
10 relevant action on SGLT1 in other tissues, confirming a more complex and fine participation of
11
12 these Na-glucose cotransporters in glucose homeostasis, and remarking the need of further studies
13
14 addressing the extra-renal mechanisms of action of these fascinating compounds.
15
16
17
18
19
20
21
22
23

24 **Acknowledgements**

25
26
27 We thank Dr. Brenno D. Astiarraga for his helpful suggestions on glucagon determinations.
28
29
30
31
32
33
34

35 **Funding**

36
37
38 This work has been supported by an unrestricted grant from Astra Zeneca. The company did not
39
40 have any role in designing the study, generating and analyzing data, writing the manuscript. FD
41
42 received support from the Italian Ministry of Research (grant n. 2010JS3PMZ_008).
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

References

- 1
2
3
4
5 [1] Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical
6
7 prospects. *Nat Rev Endocrinol* 2012;8(8):495-502.
8
9
10 [2] Lambers Heerspink HJ, de Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-
11
12 regulating drug with diuretic properties in subjects with type 2 diabetes. *Diabetes Obes Metab*
13
14 2013;15:853-62.
15
16 [3] Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin
17
18 sensitivity but enhances endogenous glucose production. *J Clin Invest* 2014;124:509-14.
19
20
21 Erratum in: *J Clin Invest* 2014;124:2287.
22
23
24 [4] Ferrannini E, Muscelli E, Frascerra S, Baldi S, mari A, Heise T et al. Metabolic response to
25
26 sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. *J Clin Invest*
27
28 2014;124:499-508 Erratum in: *J Clin Invest* 2014;124:1868.
29
30
31 [5] Zhao FQ, Keating AF. Expression and regulation of glucose transporters in the bovine
32
33 mammary gland. *J Dairy Sci* 2007;90 Suppl 1:E76-86.
34
35
36 [6] Patel OV, Casey T, Dover H, Plaut K. Homeorhetic adaptation to lactation: comparative
37
38 transcriptome analysis of mammary, liver, and adipose tissue during the transition from
39
40 pregnancy to lactation in rats. *Funct Integr Genomics* 2011;11:193-202.
41
42
43 [7] Chen J, Williams S, Ho S, Loraine H, Hagan D, Whaley JM et al. Quantitative PCR tissue
44
45 expression profiling of the human SGLT2 gene and related family members. *Diabetes Ther*
46
47 2010;1:57-92.
48
49
50 [8] Bonner C, Kerr-Conte J, Gmyr V, Queniat G, Moerman E, Thévenet J et al. Inhibition of the
51
52 glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon
53
54 secretion. *Nat Med* 2015;21:512-7.
55
56
57
58
59
60
61
62
63
64
65

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [9] Rorsman P, Ramracheya R, Rorsman NJ, Zhang Q. ATP-regulated potassium channels and voltage-gated calcium channels in pancreatic alpha and beta cells: similar functions but reciprocal effects on secretion. *Diabetologia* 2014;57:1749-61.
- [10] Veedfald S, Plamboeck A, Deacon CF, Hartmann B, Knop FK, Vilsbøll T et al. Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. *Am J Physiol Gastrointest Liver Physiol* 2016;310:G43-51.
- [11] Mundinger TO, Cooper E, Coleman MP, Taborsky GJ Jr. Short-term diabetic hyperglycemia suppresses celiac ganglia neurotransmission, thereby impairing sympathetically mediated glucagon responses. *Am J Physiol Endocrinol Metab* 2015;309:E246-55.
- [12] Liu JJ, Lee T, DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? *Diabetes* 2012;61:2199-204.
- [13] Yu AS, Hirayama BA, Timbol G, Liu J, Diez-Sampedro A, Kepe V et al. Regional distribution of SGLT activity in rat brain in vivo. *Am J Physiol Cell Physiol* 2013;304:C240-47.
- [14] Vasu S, Moffett RC, McClenaghan NH, Flatt PR. Responses of GLP1-secreting L-cells to cytotoxicity resemble pancreatic β -cells but not α -cells. *J Mol Endocrinol* 2015;54:91-104.
- [15] Shen XX, Li HL, Pan L, Hong J, Xiao J, Hermansen K, Jeppesen PB, Li GW. Glucotoxicity and α cell dysfunction: involvement of the PI3K/Akt pathway in glucose-induced insulin resistance in rat islets and clonal α TC1-6 cells. *Endocr Res* 2012;37:12-24.
- [16] Hurlle MR, Yang L, Xie Q, Rajpal DK, Sanseau P, Agarwal P. Computational drug repositioning: from data to therapeutics. *Clin Pharmacol Ther* 2013;93:335-41.
- [17] Grieco FA, Moretti M, Sebastiani G, Galleri L, Spagnuolo I, Scafetta G et al. Delta-cell-specific expression of hedgehog pathway Ptch1 receptor in murine and human endocrine pancreas. *Diabetes Metab Res Rev* 2011;27:755-60.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [18] da Silva Xavier G, Farhan H, Kim H, Caxaria S, Johnson P, Hughes S et al. Per-arnt-sim (PAS) domain-containing protein kinase is downregulated in human islets in type 2 diabetes and regulates glucagon secretion. *Diabetologia* 2011;54:819-27.
- [19] Leclerc I, Sun G, Morris C, Fernandez-Millan E, Nyirenda M, Rutter GA. AMP-activated protein kinase regulates glucagon secretion from mouse pancreatic alpha cells. *Diabetologia* 2010;54:125-34.
- [20] Dorrell C, Schug J, Lin CF, Canaday PS, Fox AJ, Bonnah R et al. Transcriptomes of the major human pancreatic cell types. *Diabetologia* 2011;54:2832-44. Erratum in: *Diabetologia* 2013;56:1192.
- [21] Heimberg H, De Vos A, Pipeleers D, Thorens B, Schuit F. Differences in glucose transporter gene expression between rat pancreatic alpha- and beta-cells are correlated to differences in glucose transport but not in glucose utilization. *J Biol Chem* 1995;270:8971-75.
- [22] Burcelin R, Thorens B. Evidence that extrapancreatic GLUT2-dependent glucose sensors control glucagon secretion. *Diabetes* 2001;50:1282-89.
- [23] Zhang H, Liu R, Deng T, Wang X, Lang H, Qu Y, et al. The microRNA-124-iGluR2/3 pathway regulates glucagon release from alpha cells. *Oncotarget* 2016;7:24734-743.
- [24] Sandoval DA, D'Alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. *Physiol Rev* 2015;95:513-48.
- [25] Marchetti P, Lupi R, Bugliani M, Kirkpatrick CL, Sebastiani G, Grieco FA et al. A local glucagon-like peptide 1 (GLP-1) system in human pancreatic islets. *Diabetologia* 2012;55:3262-72.
- [26] Sangan CB, Jover R, Heimberg H, Tosh D. In vitro reprogramming of pancreatic alpha cells towards a beta cell phenotype following ectopic HNF4 α expression. *Mol Cell Endocrinol* 2015;399:50-9.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- [27] Li R, Zhang X, Yu L, Zou X, Zhao H. Characterization of insulin-immunoreactive cells and endocrine cells within the duct system of the adult human pancreas. *Pancreas* 2016;45:735-42.
- [28] Wilcox CL, Terry NA, Walp ER, Lee RA, May CL. Pancreatic alpha-Cell specific deletion of mouse *Arx* leads to alpha-cell identity loss. *PLoS One* 2013, p. e66214.
- [29] Dhawan S, Georgia S, Tschen SI, Fan G, Bhushan A. Pancreatic beta cell identity is maintained by DNA methylation-mediated repression of *Arx*. *Dev Cell* 2011;20:419-29.
- [30] Vieira E, Salehi A, Gylfe E. Glucose inhibits glucagon secretion by a direct effect on mouse pancreatic alpha cells. *Diabetologia* 2007;50:370-79.
- [31] Martin TD, Mitin N, Cox AD, Yeh JJ, Der CJ. Phosphorylation by protein kinase $C\alpha$ regulates RalB small GTPase protein activation, subcellular localization, and effector utilization. *J Biol Chem* 2012;287:14827-36.
- [32] Li SK, Zhu D, Gaisano HY, Brubaker PL. Role of vesicle-associated membrane protein 2 in exocytosis of glucagon-like peptide-1 from the murine intestinal L cell. *Diabetologia* 2014;57:809-18.

Legend to Figures

Figure 1

A) Expression of *Slc5a1*, *Slc2a1* and *Slc2a2* genes, encoding for SGLT1, GLUT1 and GLUT2 respectively, in untreated α TC-1 cells (white bars) and after treatment with Dapagliflozin (Dapa) 100 ng/ml for a prolonged timeframe (different tones of gray bars). Data are reported as mean \pm SD of at least six experiments. * p<0.01 vs Untreated

B) *Slc5a2* digital PCR analysis: original imaging from digital PCR are shown, with an explicative comparison between the number of copies of detected mRNA from α TC-1 cells, for the reference gene (β -actin) and in murine kidney.

C) A representative WB obtained by loading 100 μ g of alpha-cells total protein shows the extremely scarce SGLT2 presence.

Figure 2

A) Real Time PCR analysis of Laser Captured microdissected alpha- and beta-cells for pre-proglucagon, insulin and *Slc5a1* and *Slca2*. Data are reported as fold change+SD respect to beta-cells. * p<0.05 vs beta-cells.

B) Real-Time PCR analysis of relative expression of *Slc5a2* and *Slc5a1* genes in human pancreatic islets. *p<0.005 vs core; §p<0.001 vs *Slc5a2*. Gene expression is confirmed by WB analysis, showing SGLT1 and SGLT2 protein in human pancreatic islets.

C) Representative image of an intact islet, its core and its periphery before and after Laser Capture microdissection.

Figure 3

Glucagon secretion from murine α TC-1 cells, grown at 25 mmol/l glucose, in the basal state and after treatment with dapagliflozin (Dapa) 100 ng/ml for different time periods. Data are reported as

1 mean±SD of at least four experiments. The % release (100 x supernatant)/(supernatant+content) is
2 reported on the right *p<0.05 by ANOVA for repeated measures
3
4
5

6 **Figure 4**

7
8
9 Effect of two different glucose concentrations (very low: 1.1 mM and low: 5.5 mM) on glucagon
10 release from untreated and Dapagliflozin-treated α TC-1 cells.
11
12

13 Data are reported as mean±SD of at least eight experiments.
14

15
16 * p<0.01 vs Untreated
17
18
19
20

21 **Figure 5**

22
23 Effect of *Slc5a1* gene silencing on *Slc5a1* expression (real time PCR, A); digital PCR, B); pre-
24 proglucagon gene expression (C) and glucagon release at 45 min (D). Data are reported as
25
26 mean±SD of at least three experiments.
27
28

29
30 *p<0.005 vs Control; §p<0.05 vs Dapa
31
32
33
34
35

36 **Figure 6**

37
38 A) PASK and AMPK-a2 gene expression in untreated α TC-1 cells (Control), cells treated with
39 Dapagliflozin 100 ng/ml (Dapa), and cells where *Slc5a1* gene has been silenced, in the absence
40
41 (siRNA) or presence of Dapa (siRNA+Dapa).
42
43

44
45 B) Protein expression **evaluated by Western Blot analysis** (PASK and total and phosphorylated
46
47 AMPK-a2) in control cells and after 4 h of gene silencing is reported, together with the
48
49 quantification of the bands. WB is representative of three experiments.
50
51

52
53 C) Effect of high (HG) and low (LG, 5.5 mM) glucose and/or Dapa on PASK and AMPK-a2 genes.
54
55

56 *p between 0.01 and 0.005 vs Control; §p<0.05 vs HG
57
58
59
60
61
62
63
64
65

Figure 1
[Click here to download high resolution image](#)




Figure 1

Figure 2
[Click here to download high resolution image](#)





Figure 2

Figure 3
[Click here to download high resolution image](#)



	% release	
	Control	Dapa
30 min	-----	-----
45 min	-----	-----
60 min	6.2±0.7	9.3±0.8*
120 min	6.5±0.8	10.2±0.8*
240 min	6.3±0.5	9.6±0.8*
480 min	11.4±0.8	14.6±0.9*

Figure 3

Figure 4
[Click here to download high resolution image](#)




Figure 4

Figure 5
[Click here to download high resolution image](#)







Figure 5

Figure 6
[Click here to download high resolution image](#)

Figure 6



Suppl Tables

[Click here to download e-component: Suppl Tables.docx](#)

Suppl Figures

[Click here to download e-component: Suppl Figures.pptx](#)